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Background: Social support is defined as a network of family/friends who provide practical 
and emotional help. A sizable literature describes a direct relationship between social support 
and improved cancer clinical outcomes. This study explored the extent of social support and its 
potential association with survival and adverse events in geriatric lung cancer patients.
Methods: One hundred thirteen patients, who were aged 65 years or older, had incurable cancer, 
and were enrolled in one of two chemotherapy trials, completed the Lubben Social Network 
Scale, a validated instrument that measures social support. All were followed for survival and 
chemotherapy-related adverse events.
Results: The median age (range) of the cohort was 74 years (65–91), and performance scores of 
0, 1, or 2 were observed in 29%, 55%, and 16%, respectively. Forty-two percent were women. 
This cohort had a high level of social support: 81% reported they “always” had someone to 
take them to medical appointments. However, there were no gender-based differences in social 
support and no associations between social support and either survival or adverse events.
Conclusion: In this cohort of geriatric lung cancer patients – all of whom were treated during 
a clinical trial – there was a high level of social support. However, there were no gender-based 
differences in extent of social support, and the latter did not predict clinical outcomes.
Keywords: social support, lung cancer, elderly, adverse events, survival
Social support is defined as a network of family and friends who provide practical help 
and emotional encouragement.1 A sizable but controversial literature describes a direct 
relationship between high levels of social support and improved clinical outcomes in 
cancer patients.2–5 Falagas and colleagues recently completed a systematic review of 
the effect of psychosocial factors on clinical outcomes among breast cancer patients.4 
Reporting on 31 studies, these investigators observed that over 80% of studies detected 
a direct, statistically significant association between longer survival and at least one 
psychosocial parameter, which included strong social support. Although an exact 
explanation for this direct relationship between social support and improved cancer 
outcomes has not been elucidated, it appears that factors such as reliable transportation 
to medical appointments and closer monitoring at home for side effects may explain 
this relationship. The foregoing observations underscore a need to study social support 
further in other cancer settings.
Social support is highly relevant to geriatric lung cancer patients. In general, 
geriatric patients suffer from lack of social support because of the demise of their peers Cancer Management and Research 2009:1 62
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and consequent social isolation.6,7 Often times, the older an 
individual, the less social support available.6,7 Women are 
especially vulnerable because they often outlive men,8 and, 
importantly, women often provide a major component of 
social support within families, thus leaving little such support 
directly available for themselves.9 At the same time, however, 
lung cancer patients specifically have greater needs for social 
support because of diminished mobility, concomitant morbid-
ity, and an accelerated decline in overall health status.10–13 
Thus, the literature on social support raises questions relevant 
to geriatric lung cancer patients and women in particular.
In view of this previously reported association between 
social support and improved clinical outcomes, the goals of 
the present study were as follows: 1) To provide descriptive 
data on the extent of social support in geriatric lung cancer 
patients about to start cancer treatment and to explore whether 
such social support predicts clinical outcomes and 2) to 
explore the existence of gender differences in social support 
among geriatric lung cancer patients.
Materials and methods
Overview
This study was conducted within the North Central Cancer 
Treatment Group, a national cancer cooperative group that is 
funded in part by the National Cancer Institute. Questionnaire 
and clinical trial data from two separate cancer therapeutic 
trials, N9921 and N0222 were utilized. These two trials 
recruited patients between February 2000 and February 
2001 and between December 2004 and February 2006, 
respectively. The present study’s design was formulated prior 
to the initiation of the first trial and entailed merging and 
analyzing data from both of these prospectively conducted 
clinical trials.
Patient eligibility
Eligibility criteria for these two trials focused on selecting 
patients who could tolerate the chemotherapy agents, gefitinib, 
paclitaxel, and carboplatin, which were used in one or both 
of the trials mentioned above. These criteria are described in 
greater detail elsewhere,14,15 but relevant factors consistent 
between both trials included the following: 1) patient aged 
65 years or older; 2) Eastern Cooperative Group performance 
score (an often-utilized score that describes the level of function 
of cancer patients) of 0, 1, or 2; 3) histologic or cytologic 
confirmation of non-small cell lung cancer; 4) unresectable 
cancer; 5) no prior chemotherapy; 6) physician-anticipated 
life expectancy of 12 weeks or longer; and 7) absence of a 
major medical illness that would preclude participation in a 
therapeutic cancer clinical trial. In addition, all patients had 
to have had adequate organ function, as demonstrated by an 
acceptable hemogram, liver function tests, and serum creati-
nine at the time of study enrollment. Other eligibility criteria 
were more specific to each chemotherapy regimen patients 
were about to receive, such as, for example, an exclusion 
of patients with severe neuropathy in the event they were to 
receive paclitaxel. Otherwise, there were no major differences 
in eligibility criteria between the two studies.
Patient enrolment and follow-up
All eligible patients completed the Lubben Social Network 
Scale within 14 days of trial registration and prior to receiv-
ing any chemotherapy. This 12-item instrument has been 
previously validated, has been tested in a variety of settings, 
and includes questionnaire items that are highly germane 
to defining extent of social support.16 Thereafter patients 
were treated with one of the following chemotherapy regi-
mens: 1) weekly carboplatin and paclitaxel (intravenous); 2) 
weekly carboplatin and paclitaxel (intravenous) potentially 
for four months followed by daily gefitinib (oral); or 3) daily 
gefitinib (oral). Patients were to continue cancer therapy until 
evidence of cancer progression, until unacceptable side effects 
occurred, or, for a maximum of four months, if they were 
receiving conventional chemotherapy. All patients were seen 
by their treating oncologist every 3–4 weeks. They were moni-
tored indefinitely for cancer therapy-related side effects by 
means of the Common Terminology Criteria, version 2 from 
the National Cancer Institute.17 Tumor response as assessed by 
the RECIST criteria,18 and overall survival was assessed.
statistical analyses
The sample sizes for the two individual trials were calcu-
lated to obtain adequate statistical power for the primary 
aims of these clinical trials, not for the social support aims. 
Nonetheless, for the current study, we conducted a retrospec-
tive power calculation for the comparisons of two indepen-
dent means to evaluate the power available for comparing 
the Lubben Social Support score by the dichotomous factors 
of gender, performance score, and severe adverse events. 
The sample size of 113 (56 in each group) with an observed 
standard score deviation of 17 and an observed median social 
support score of 72 yields 84% power to detect a difference of 
12 points (60 versus 72) using a two-sided alpha of 0.007.
Scores from the Lubben Social Support Network (Items 
1–10 on Table 2) were summed for analyses and then 
transformed to a 100% scale. A score of 0 represents the 
lowest possible level of social support; whereas, a score of Cancer Management and Research 2009:1 63
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100 represents the highest possible level of social support. 
To transform the scores to a 100% scale, a patient’s individual 
score was divided by the patient’s possible range account-
ing for any missed items (maximum minus minimum) and 
multiplied by 100.
A rank sum test was used to evaluate whether social 
support scores differed based on the characteristics of 
gender, age ( = 70), and performance status. Similarly, 
a rank sum test was also used to evaluate whether social 
support scores differed between patients who suffered more 
severe adverse events (grade 3 or worse) versus those who 
did not. Time-to-cancer progression was defined as the time 
from registration to documentation of cancer progression. 
Survival time was defined as the time from study registration 
to death due to any cause. The distribution of survival time 
was estimated using the Kaplan–Meier method. A Cox 
proportional hazards model, which adjusted for cancer treat-
ment, performance score, age, gender, and sum of target 
lesions at baseline, was used to evaluate whether social 
support scores were related to time-to-cancer progression 
or overall survival. In order to illustrate the influence of 
social support on overall survival, we divided the cohort 
by social support score quartiles. No widely accepted cut-
points exist to separate social support into categories, so 
quartiles were used to distribute evenly the 113 patients into 
four groups. A logistic regression model, which adjusted 
for the same baseline factors mentioned above, was used 
to assess relationships between social support and adverse 
events. Because of the exploratory nature of these analyses 
and because of the number of statistical tests performed, a 
p-value of  0.01 was considered statistically significant. This 
decision to utilize this p-value was based on the computation 
that the overall conventional alpha level is 0.05 and that 
seven multiple comparisons were made with a Bonferroni 
adjustment. All statistical analyses were conducted with SAS 
software (SAS Institute, Cary, NC, USA).
Results
Demographics
A total of 113 patients met the eligibility criteria, received 
chemotherapy on a clinical trial, and therefore participated in 
the current study. One patient did not receive chemotherapy, 
and two did not meet the eligibility criteria described earlier; 
thus, these three patients are not included in the analyses. 
Forty-two percent of the cohort consisted of women, and 
the median age (range) was 74 years (65, 91). At the time of 
study entry, a performance score of 0, 1, or 2 was observed 
in 29%, 55%, and 16% of the cohort, respectively. Other 
demographics are shown in Table 1.
social support scores, gender,  
and clinical prediction
Lubben Social Network Scale data are summarized in Table 2. 
Of note, 44% of patients reported that they see nine or more 
relatives at least once a month, and 27% reported that they 
see five to eight. Forty-eight percent see such relatives daily. 
In addition, 73% reported that when they have an important 
decision to make, they “always” have someone to talk with. 
Table 1 Baseline patient characteristics*
N0222 N9921 Overall
N 63 50 113
Median age (range) 76 (65–91) 73 (65–85) 74 (65–91)
Gender  
  Female  
  Male
 
27 (43)  
36 (57)
 
20 (40)  
30 (60)
 
47 (42)  
66 (58)
Performance status  
  0  
  1  
  2
 
18 (29)  
38 (60)  
7 (11)
 
15 (30)  
24 (48)  
11 (22)
 
33 (29)  
62 (55)  
18 (16)
Stage  
  iB  
  iiiA  
  iiiB  
  iV  
  Locally advanced  
  Metastatic
 
1 (2)  
2 (3)  
12 (19)  
48 (76)  
0 (0)  
0 (0)
 
0 (0)  
0 (0)  
0 (0)  
0 (0)  
7 (14)  
44 (86)
 
1 (1)  
2 ( 2)  
12 (11)  
48 (42)  
7 (6)  
43 (38)
Note: *Parentheses denote the percentage of patients (%) unless otherwise specified.Cancer Management and Research 2009:1 64
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Table 2 Lubben social network scale*
N %
  1.    how many relatives do you see or hear from at least once a month? (note: include in-laws with relatives.)
  Zero 2 2
  One 5 4
  Two 5 4
  Three or Four 20 18
  Five to eight 31 27
  nine or More 50 44
  2.   Tell me about the relative with whom you have the most contact. how often do you see or hear from that person?
  Missing, did not answer 1 1
  Monthly 2 2
  Monthly 1 1
  A few times a month 6 5
  Weekly 21 19
  A few times a week 28 25
  Daily 54 48
  3.    how many relatives do you feel close to? That is, how many of them do you feel at ease with, can talk to about 
private matters, or can call on for help?
  Missing 1 1
  Zero 0 0
  One 6 5
  Two 15 13
  Three or four 37 33
  Five to eight 20 18
  nine or more 34 30
  4.    Do you have any close friends? That is, how many of them do you feel at ease with, can talk to about private 
matters, or can call on for help?
  Missing 1 1
  Zero 9 8
  One 13 12
  Two 14 12
  Three or four 40 35
  Five to eight 17 15
  nine or more 19 17
  5.  how many of these friends do you see or hear from at least one a month?
  Missing 1 1
  Zero 10 9
  One 11 10
  Two 15 13
  Three or four 40 35
  Five to eight 20 18
  nine or more 16 14
  6.   Tell me about the friend with whom you have the most contact. how often do you see or hear from that person?
  Missing 6 5
  Monthly 11 10
  Monthly 4 4
  A few times a month 9 8
  Weekly 28 25
  A few times a week 29 26
  Daily 26 23
(Continued)Cancer Management and Research 2009:1 65
social support in elderly lung cancer patients Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Table 2 (Continued)
N %
  7.   When you have an important decision to make, do you have someone you can talk to about it?
  Missing 3 3
  Always 82 73
  Very often 9 8
  Often 8 7
  sometimes 9 8
  seldom 2 2
  never 0 0
  8.   When other people you know have an important decision to make, do they talk to you about it?
  Missing 3 3
  Always 23 20
  Very often 16 14
  Often 24 21
  sometimes 33 29
  seldom 10 9
  never 4 4
9a.    Dose anybody rely on you to do something for them each day? For example: shopping, cooking, dinner, doing repairs, 
cleaning, etc.?
  Missing 8 7
  no 64 57
  Yes 41 36
9b.    Do you help anybody with things like shopping, filling out forms, doing repairs, providing child care, etc.? (was only 
to be answered if Question #9a was answered “No”)
  Missing, did not answer or was not supposed to answer 54 48
  Always 1 1
  Very often 4 4
  Often 7 6
  sometimes 13 12
  seldom 16 14
  never 18 16
10.  Do you live alone or with other people?
  Missing 3 3
  Live with spouse 74 65
  Live with other relatives or friends 9 8
  Live with other unrelated individuals (eg, paid help) 2 2
  Live alone 25 22
11.   When you have medical appointments, do you have friends or relatives who can help you get there and back?
  Missing 2 2
  Always 93 82
  Very often 4 4
  Often 11 10
  sometimes 1 1
  seldom 1 1
  never 1 1
12.    if you were able to have any side effects from the medication, do you have friends or relatives who can help?
  Missing 2 2
  Always 80 71
  Very often 9 8
  Often 17 15
  sometimes 4 4
  seldom 1 1
  never 0 0
Note: *Percentages may not add up to 100% because of rounding.Cancer Management and Research 2009:1 66
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Finally, 82% reported that they “always” have someone 
who can take them to their medical appointments, and 71% 
reported that they “always” have someone from whom they 
can seek help if they have medication side effects.
The median transformed social support score for the 
entire cohort (range) was 72 (30–100). It should be noted 
that, although normative reference data are not readily avail-
able, a community-based study among a group of  7,524 
older individuals observed a similarly-derived, average 
social support score of 63.19 Among women and men in the 
present study, the average score was not statistically different: 
72 in both (rank sum, p = 0.87) (Figure 1). Additionally, there 
was no statistically significant difference in social support 
scores among patients with an Eastern Cooperative Oncology 
Group performance score of 0 versus 1 and 2: median score 
74 and 70 (rank sum, p = 0.06).
Similarly, there was no consistent evidence that social 
support scores predicted clinical outcomes. Although there 
was a trend to suggest that higher social support scores 
ironically predicted a shorter time-to-cancer-progression 
(p = 0.02; hazard ratio [HR] =1.02; 95% confidence interval 
[CI]: 1.00–1.03), these scores did not predict overall survival 
(p = 0.34; HR = 1.01; 95% CI: 0.99–1.02) (Figure 2). There 
was also no statistically significant difference in scores 
between patients who suffered grade 3 or worse adverse 
events and those who did not: median score 74 and 70 (rank 
sum, p = 0.28) (adjusted logistic regression p = 0.70; odds 
ratio [OR] = 1.00; 95% CI: 0.97–1.02) (Table 3).
Discussion
The present study was designed to assess and evaluate the 
role of social support in a group of geriatric non-small cell 
lung cancer patients who were enrolled in two different cancer 
therapeutic clinical trials. This study found that this cohort 
of geriatric patients had high levels of social support, as 
suggested by the fact that 81% reported that they “always” had 
someone who could take them to medical appointments, and 
71% reported that they “always” had someone from whom 
they could seek help if they had medication side effects. 
However, social support was not associated with improved 
survival or diminished side effects from chemotherapy. 
Moreover, no differences were observed between men and 
women in terms of baseline social support. Thus, although 
previous studies have reported that social support carries a 
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positive impact on clinical outcomes and although gender dif-
ferences in extent of social support have been hypothesized, 
the present study did not observe such findings.
Why might the results of this study be divergent from 
the others that preceded it? First, relying on a clinical trial 
to answer such questions provides a solid infrastructure 
that ensures reliable outcome data. The fact that all clinical 
trial participants were followed prospectively in such a 
thorough and systematic fashion makes it unlikely that 
patients – particularly those who have poor social support 
and who are thereby especially vulnerable to being lost to 
follow up – would, in fact, be lost to follow up. Such artifi-
cially compromised outcomes were side-stepped by building 
the study around two clinical trials, as was done here. Thus, 
the present study’s meticulous follow up may have allowed 
for a more definitive and accurate assessment of the predic-
tive capabilities – or lack thereof – of social support.
Second, and more importantly, one might argue that 
patients’ willingness to participate in a clinical trial is associ-
ated with a high level of social support and that this selection 
bias may have contributed to the lack of differences between 
groups. The fact that 82% of patients reported that they 
“always” had someone to bring them to medical appointments 
speaks to the possibility that this group as a whole has a high 
level of social support. Similarly, the median social support 
score of 72 in this study appears greater than the 63 score 
Table 3 social support scores and adverse events
Social support score 
(median)
p-value*
grade 3+ adverse events:  
  Yes (n = 66)  
  no (n = 47)
 
74  
70
 
0.28
grade 3+ nonhematologic adverse events   
  Yes (n = 63)  
  no (n = 50)
 
74  
70
 
0.14
grade 3+ hematologic adverse events  
  Yes (n = 9)  
  no (n = 104)
 
64  
72
 
0.36
Note: *Per the rank sum test.
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0–25%, median = 7.6 months, n = 26
25–50%, median = 9.8 months, n = 26
50–75%, median = 8.3 months, n = 29
75–100%, median = 8.6 months, n = 32
Log-Rank p = 0.34
36
Figure 2 Kaplan–Meier survival curves are shown based on extent of social support as shown in quartiles.*
Notes: *25th percentile, social support score range (0–57); 50th percentile, social support score range (58–71); 75th percentile, social support score range (72–79); and 100th 
percentile, social support score range (80–100).Cancer Management and Research 2009:1
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derived from a community-based study, an observation that 
also suggests cancer clinical trial participants have high levels 
of social support.19 In short, although the findings from this 
study suggest that social support does not influence clinical 
outcomes, these findings might pertain to only a culled 
group of geriatric clinical trial participants. Future studies 
may choose to focus further on the extent of social support 
among geriatric patients who participate in clinical trials, 
and further studies may also choose to study further whether 
social support is a predictive factor for the patients who can 
and do enroll in cancer clinical trials.
Two final points merit further discussion. First, although 
the current study did not find that social support was predictive 
of outcomes, there are a variety of other potentially clinically 
relevant factors that had not been captured and adjusted for. 
These include socioeconomic status, ongoing tobacco use, use 
of nutritional supplements, as well as several other factors. 
Other investigators may choose to further study the issue of 
social support in the context of these other factors. Second, 
although this study found that social support is not associated 
with clinical outcomes among elderly lung cancer patients, 
there remains no question that these patients have major needs 
that are likely exacerbated by a lack of social support. Patients 
with metastatic non-small cell lung cancer suffer from a poor 
prognosis, as seen from both studies presented here where the 
prognosis was poor, and previous studies have demonstrated 
that elderly patients suffer from a wide constellation of cancer-
related symptoms, including depression, guilt, debility, pain, 
and dyspnea.10–13 Although the present study did not observe 
an association between social support and clinical outcomes, 
there nonetheless remains a strong need for maximizing social 
support to help with some of the cancer-related challenges 
these patients face.
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